Cargando…

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care provid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Sulais, Eman, AlAmeel, Turki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966952/ https://www.ncbi.nlm.nih.gov/pubmed/32021084 http://dx.doi.org/10.2147/BTT.S236433

Ejemplares similares

Methotrexate in inflammatory bowel disease: A primer for gastroenterologists
por: AlAmeel, Turki, et al.
Publicado: (2022)

Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States
por: Al Sulais, Eman, et al.
Publicado: (2021)

The Prevalence of Irritable Bowel Syndrome Among Board-Certified Medical Doctors In Saudi Arabia: A Cross-sectional Study
por: AlAmeel, Turki, et al.
Publicado: (2019)

Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study
por: AlAskar, Dimah, et al.
Publicado: (2020)

The psychological impact of COVID-19 pandemic on physicians in Saudi Arabia: A cross-sectional study
por: Al Sulais, Eman, et al.
Publicado: (2020)

Bowel preparation: The elderly, the hospitalized, and the colonoscope
por: AlAmeel, Turki
Publicado: (2018)

Barriers to research productivity among gastroenterologists and hepatologists in Saudi Arabia
por: AlSardi, Mais, et al.
Publicado: (2020)

A cross-sectional survey on the psychological impact of the COVID-19 pandemic on inflammatory bowel disease patients in Saudi Arabia
por: Mosli, Mahmoud, et al.
Publicado: (2020)

The great wall of inflammatory bowel disease
por: Al Sulais, Eman, et al.
Publicado: (2022)

Human papillomavirus bowel colonization in inflammatory bowel disease: A comparative case control study
por: Mosli, Mahmoud H., et al.
Publicado: (2022)

Tranexamic Acid Treatment of Life-Threatening Hematuria in Polycystic Kidney Disease
por: AlAmeel, Turki, et al.
Publicado: (2011)

Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials
por: AlAmeel, Turki, et al.
Publicado: (2023)

The missing “C”: Crohn's, colitis and coping
por: AlAmeel, Turki, et al.
Publicado: (2019)

Is Solitary Rectal Ulcer Syndrome Uncommon in Saudi Arabia?
por: Al Naser, Zahra, et al.
Publicado: (2017)

Extrahepatic cholangiocarcinoma with prolonged survival: a case report
por: Al-Zahir, Mohammed Z., et al.
Publicado: (2017)

A call for structured re-opening of endoscopy services during the COVID-19 pandemic
por: Almalki, Ahmad S., et al.
Publicado: (2020)

Response to A Al-Judaibi et al.: Barriers to research productivity among physicians in Saudi Arabia: Taking a deep dive into the world of academia
por: Al sahafi, Majid, et al.
Publicado: (2021)

Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia—the community, the physicians, and the disease: Where's the hold-up?
por: Sardi, Mais Al, et al.
Publicado: (2019)

Tools for managing IBD in obese patients: Get JAK in the box!
por: Alrammah, Hanan M., et al.
Publicado: (2021)

Advances in the Diagnosis and Management of Inflammatory Bowel Disease: Challenges and Uncertainties
por: Mosli, Mahmoud, et al.
Publicado: (2014)

Colobronchial fistula presenting with persistent pneumonia in a patient with Crohn's disease: a case report
por: AlAmeel, Turki, et al.
Publicado: (2009)

A Middle-aged Woman with a Persistent Gastrointestinal Bleed
por: AlAmeel, Turki, et al.
Publicado: (2011)

Saudi Gastroenterology Association Position Statement on Privilege and Credentialing for Performing Endoscopic Retrograde Cholangiopancreatography In Saudi Arabia
por: Alharbi, Ahmad, et al.
Publicado: (2014)

Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
por: Mosli, Mahmoud H., et al.
Publicado: (2022)

Current status of biosimilars in the treatment of inflammatory bowel diseases
por: Park, Dong Il
Publicado: (2016)

Insights on the use of biosimilars in the treatment of inflammatory bowel disease
por: Zheng, Michael K, et al.
Publicado: (2017)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Current and new antitumor necrosis factor agents in perspective
por: Maini, Ravinder N
Publicado: (2004)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
por: Park, Sang Hyoung, et al.
Publicado: (2020)

Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
por: Najeeb, Hala, et al.
Publicado: (2022)

UDCA in UC: A true disease modifier or symptoms reliever?
por: Sulais, Eman Al
Publicado: (2021)

Study of tumor necrosis factor receptor in the inflammatory bowel disease
por: Souza, Roberta Figueiroa, et al.
Publicado: (2023)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
por: Rawla, Prashanth, et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Idiopathic Myointimal Hyperplasia of Mesenteric Veins (IMHMV) with two spontaneous bowel perforations: A case report and literature review
por: Almumtin, Ahmed, et al.
Publicado: (2021)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease
por: Al-Meghaiseeb, Ebtissam Saleh, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3sbbf7fkunttamipv4l5dnjk1a